Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease

被引:54
作者
Nowak, Albina [1 ]
Mechtler, Thomas [2 ]
Kasper, David C. [2 ]
Desnick, Robert J. [3 ]
机构
[1] Univ Zurich, Univ Hosp Zurich, Dept Internal Med, Ramistr 100, CH-8091 Zurich, Switzerland
[2] ARCHIMED Life Sci, Leberstr 20, A-1110 Vienna, Austria
[3] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA
关键词
Lyso-Gb3; Dried blood spots (DBS); Fabry disease; alpha-Galactosidase A; ENZYME REPLACEMENT THERAPY; ALPHA-GALACTOSIDASE; AGALSIDASE-BETA; GLOBOTRIAOSYLSPHINGOSINE; PLASMA; MUTATIONS; DIAGNOSIS; VARIANT;
D O I
10.1016/j.ymgme.2017.06.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fabry disease (FD), an X-linked lysosomal storage disorder, results from the deficient activity of alpha-galactosidase A (a-Gal A) and the accumulation of its substrates, globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine (Lyso-Gb3). Here, we compared the levels of Lyso-Gb3 in dried blood spots (DBS) and sera in affected males and heterozygotes with the "Classic" and "Later-Onset" phenotypes. Methods: The Lyso-Gb3 concentrations in DBS and sera from 56 FD patients were determined by highly sensitive electrospray ionization liquid chromatography tandem mass spectrometry. Results: The serum Lyso-Gb3 levels in 18 and 5 affected males with the Classic and Later-Onset phenotypes, were 61 +/- 38 and 14 +/- 12 ng/mL, respectively. Lyso-Gb3 levels in 30 females from Classic families and three females from Later-Onset families were 10 +/- 5.4 and 2.4 +/- 1.0 ng/mL, respectively. The linear regression model with serum Lyso-Gb3 as the dependent variable and DBS Lyso-Gb3 an independent variable was described by the function y = -1.83 + 1.68 * x and showed a high coefficient of determination, R-2 = 0.976. T Conclusion: DBS provides a convenient, sensitive, and reproducible source to measure Lyso-Gb3 levels for diagnosis, initial phenotypic assignment, and therapeutic monitoring in patients with Fabry disease. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:320 / 324
页数:5
相关论文
共 31 条
  • [1] Elevated globotriaosylsphingosine is a hallmark of Fabry disease
    Aerts, Johannes M.
    Groener, Johanna E.
    Kuiper, Sijmen
    Donker-Koopman, Wilma E.
    Strijland, Anneke
    Ottenhoff, Roelof
    van Roomen, Cindy
    Mirzaian, Mina
    Wijburg, Frits A.
    Linthorst, Gabor E.
    Vedder, Anouk C.
    Rombach, Saskia M.
    Cox-Brinkman, Josanne
    Somerharju, Pentti
    Boot, Rolf G.
    Hollak, Carla E.
    Brady, Roscoe O.
    Poorthuis, Ben J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (08) : 2812 - 2817
  • [2] [Anonymous], 1908, PROBABLE ERROR MEAN, V6, P1
  • [3] Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
    Arends, Maarten
    Wanner, Christoph
    Hughes, Derralynn
    Mehta, Atul
    Oder, Daniel
    Watkinson, Oliver T.
    Elliott, Perry M.
    Linthorst, Gabor E.
    Wijburg, Frits A.
    Biegstraaten, Marieke
    Hollak, Carla E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (05): : 1631 - 1641
  • [4] Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
    Banikazemi, Maryam
    Bultas, Jan
    Waldek, Stephen
    Wilcox, William R.
    Whitley, Chester B.
    McDonald, Marie
    Finkel, Richard
    Packman, Seymour
    Bichet, Daniel G.
    Warnock, David G.
    Desnick, Robert J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) : 77 - 86
  • [5] Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy
    Chen, Kuan-Hsuan
    Chou, Yueh-Ching
    Hsiao, Chen-Yuan
    Chien, Yueh
    Wang, Kang-Ling
    Lai, Ying-Hsiu
    Chang, Yuh-Lih
    Niu, Dau-Ming
    Yu, Wen-Chung
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 486 : 293 - 299
  • [6] Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation
    Chien, Yin-Hsiu
    Bodamer, Olaf A.
    Chiang, Shu-Chuan
    Mascher, Hermann
    Hung, Christina
    Hwu, Wuh-Liang
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (05) : 881 - 885
  • [7] Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy
    Desnick, RJ
    Brady, R
    Barranger, J
    Collins, AJ
    Germain, DP
    Goldman, M
    Grabowski, G
    Packman, S
    Wilcox, WR
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (04) : 338 - 346
  • [8] Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733
  • [9] X-chromosome inactivation in female patients with Fabry disease
    Echevarria, L.
    Benistan, K.
    Toussaint, A.
    Dubourg, O.
    Hagege, A. A.
    Eladari, D.
    Jabbour, F.
    Beldjord, C.
    De Mazancourt, P.
    Germain, D. P.
    [J]. CLINICAL GENETICS, 2016, 89 (01) : 44 - 54
  • [10] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
    Eng, CM
    Guffon, N
    Wilcox, WR
    Germain, DP
    Lee, P
    Waldek, S
    Caplan, L
    Linthorst, GE
    Desnick, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 9 - 16